InstalabLoading...
InstalabLoading...
Syphilis is resurging. Cases in the United States have climbed every year for more than a decade, and congenital syphilis (infection passed from mother to baby during pregnancy) has risen sharply alongside them. The disease is curable with a single shot of penicillin when caught early, but it can quietly damage the brain, eyes, heart, and blood vessels if it goes undetected. The RPR (Rapid Plasma Reagin) screen is the front line: a simple, inexpensive blood test designed to flag active infection and tell you whether treatment is working.
What makes RPR different from other syphilis tests is that it reflects what is happening right now. A treponemal test (the other main category of syphilis testing) tells you whether you have ever been infected, and it stays positive for life even after successful treatment. RPR, by contrast, produces a titer, a number that rises with active disease and falls after treatment. That makes it uniquely useful for two things: catching new infections and confirming that an old one has been cured.
RPR does not detect the syphilis bacterium (Treponema pallidum) directly. Instead, it detects antibodies your immune system produces in response to cell damage caused by the infection. The test uses a mixture of cardiolipin, lecithin, and cholesterol (fat-like molecules found in cell membranes) as bait. When your blood contains enough of these damage-associated antibodies, the test is "reactive" and reports a titer such as 1:1, 1:4, 1:16, or 1:32. The higher the titer, the more antibody is circulating, which generally tracks with how active the infection is.
Because the antibodies RPR detects are triggered by tissue damage rather than by the bacterium itself, the test is not perfectly specific. Conditions that cause inflammation or immune activation for reasons other than syphilis, such as autoimmune disease, pregnancy, or certain viral infections, can sometimes trigger a positive RPR in someone who does not have syphilis. These are called biological false positives, and they are the main reason a reactive RPR always requires a confirmatory treponemal test before you can be sure the result means syphilis.
Your RPR result will come back as one of two things: non-reactive (normal) or reactive with a titer. A non-reactive result means no concerning level of these antibodies was detected. A reactive result is reported as a dilution ratio.
| RPR Result | What It Suggests |
|---|---|
| Non-reactive | No evidence of active syphilis. Does not completely rule out very early or very late infection if clinical suspicion is high. |
| Reactive, low titer (1:1 to 1:4) | Could be early infection, late/latent infection, previously treated infection that has not fully cleared antibodies, or a false positive. Needs treponemal confirmation. |
| Reactive, moderate titer (1:8 to 1:16) | Suggests active or recent infection. Most rapid point-of-care syphilis tests perform best at titers of 1:8 and above. |
| Reactive, high titer (1:32 or higher) | Strongly suggests active, infectious syphilis. Associated with higher risk of neurosyphilis (infection of the brain and spinal cord). |
A single RPR number is a snapshot. The real power of the test comes from comparing two readings over time, because the direction of change tells you more than any single value.
When syphilis goes untreated, it can invade the nervous system. In a study of 326 adults with syphilis, a serum RPR titer of 1:32 or higher was a strong predictor of abnormal spinal fluid findings consistent with neurosyphilis, and people with an active HIV infection and weakened immune function faced even greater risk. A separate study of 165 HIV-negative people who failed initial syphilis treatment found that male sex, RPR above 1:32, and elevated white blood cells in the spinal fluid were the strongest predictors of neurosyphilis in that group.
If your RPR comes back at 1:32 or higher, the next step is a conversation with an infectious disease specialist about whether a lumbar puncture (spinal tap) is warranted to check for nervous system involvement. This is especially true if you have any neurological symptoms such as vision changes, hearing loss, or headaches.
Syphilis during pregnancy can cause stillbirth, low birth weight, and congenital syphilis in the newborn. In a study of over 22,000 pregnant women in Nairobi, those with a reactive RPR had roughly four times the risk of low birth weight or stillbirth compared to uninfected mothers. Even after antenatal treatment, the risk of adverse outcomes remained about 2.5 times higher than in women who were never infected, which means early detection and treatment matter enormously but do not eliminate risk entirely.
In Uganda, maternal syphilis was linked to a 3.8% rate of congenital syphilis among newborns. Younger mothers and those with untreated genital symptoms were at highest risk. Among infants born to mothers with infectious syphilis, about three quarters had a non-reactive RPR by 3 months of age after treatment, and 96% eventually cleared completely.
After successful treatment, your RPR titer should fall by at least fourfold within 6 to 12 months (for example, from 1:16 down to 1:4 or lower). But in some people, the titer drops part of the way and then plateaus, never reaching non-reactive. This is called the serofast state. A meta-analysis of 17 studies found that people with HIV, those with latent syphilis, and those with low starting titers were more likely to become serofast.
Being serofast does not necessarily mean treatment failed. It often reflects an immune memory that persists after the bacteria have been cleared. But it does make follow-up trickier, because the titer stops giving you clean information about whether the infection is gone. If your titer stays flat after treatment, your doctor may recommend retreatment with additional doses of penicillin, which leads to an additional fourfold decline in about half of cases.
RPR is a useful but imperfect test. Several situations can produce results that do not reflect your true syphilis status.
Understanding the difference between these two categories of syphilis testing is essential for interpreting your results. RPR is a nontreponemal test. It reflects current disease activity and produces a titer that changes over time. Treponemal tests (such as TPPA, TPHA, or automated immunoassays like the Architect Syphilis TP) detect antibodies against the actual syphilis bacterium and generally remain positive for life once you have been infected, regardless of treatment.
Neither test alone tells the whole story. RPR can miss early or late infections where antibody levels are low, and it produces false positives. Treponemal tests are more specific to syphilis but cannot distinguish a current infection from one you had and treated ten years ago. The standard approach pairs both: RPR for activity and monitoring, treponemal testing for confirmation and detection of past infection.
A study of over 309,000 samples in the Greater Toronto Area found that switching from RPR-first screening to treponemal-first screening increased confirmed positive rates by 10.3 per 100,000, largely by catching late latent cases that RPR alone would have missed. In British Columbia, implementing a treponemal-first algorithm with PCR (a DNA-based test that detects the bacterium directly) identified many previously undiagnosed late latent cases.
A single RPR reading is a starting point, not a conclusion. The real clinical value comes from serial titers. After treatment, you should have your RPR rechecked at 6 months and 12 months to confirm a fourfold decline. If you are living with HIV, more frequent monitoring (every 3 months) is reasonable because response can be slower and reinfection risk may be higher.
RPR titers can change by fourfold or more even within days of diagnosis, before any treatment is given. In a study of 766 people with syphilis, about 15% had a fourfold titer change between their diagnosis date and their treatment date. This means the baseline titer used to judge treatment success should ideally be drawn on the same day treatment is given. If there is a gap of more than a few days, consider repeating the RPR at the time of treatment so you have an accurate starting point.
For people at ongoing risk (sexually active with multiple partners, men who have sex with men, people living with HIV), screening RPR at least annually, and as often as every 3 months in high-risk settings, aligns with current guidelines and the goal of catching reinfection early.
If your RPR is non-reactive and you have no symptoms or recent high-risk exposure, no immediate follow-up is needed. Continue screening at whatever interval fits your risk profile.
If your RPR is reactive, the next step is always a confirmatory treponemal test (such as TPPA or a treponemal immunoassay). A reactive RPR with a positive treponemal test confirms syphilis, either current or past. Your doctor will then stage the infection based on your history, symptoms, and titer level to determine the right treatment. A reactive RPR with a negative treponemal test is most likely a biological false positive, but it may warrant repeat testing in a few weeks if risk factors are present.
If your titer is 1:32 or higher, or if you have any neurological or eye symptoms, an infectious disease specialist should evaluate you for possible neurosyphilis. If you are pregnant with a reactive RPR, immediate confirmatory testing and treatment are urgent to reduce the risk of congenital syphilis. Companion tests to consider alongside RPR include an HIV test (syphilis and HIV frequently co-occur and each worsens the other), a complete STI panel, and, if you have a confirmed diagnosis, a complete blood count and basic metabolic panel before starting treatment.
Evidence-backed interventions that affect your RPR Screen level
RPR Screen is best interpreted alongside these tests.